GBM Stock Chart & Stats
€1.06
-€0.05(-5.46%)
At close: 4:00 PM EDT
€1.06
-€0.05(-5.46%)
Day’s Range― - ―
52-Week Range€0.56 - €2.28
Previous CloseN/A
Volume10.38K
Average Volume (3M)2.39K
Market Cap
€111.55M
Enterprise Value€61.11
Total Cash (Recent Filing)€36.67M
Total Debt (Recent Filing)€8.00M
Price to Earnings (P/E)―
Beta0.68
Next Earnings
Nov 10, 2026EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.17
Shares Outstanding103,397,514
10 Day Avg. Volume622
30 Day Avg. Volume2,388
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)3.39
Price to Sales (P/S)1248.52
P/FCF Ratio-0.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€2.72Price Target Upside156.79% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.76
Revenue Forecast (FY)€577.80K
Bulls Say, Bears Say
Bulls Say
Regulatory ProgressAdvancing FDA review and completed prelicensure inspections represent meaningful progress toward a potential product approval. If the timeline holds, INO-3.11k could move Inovio from development-stage operations toward commercialization and create a foundation for recurring product-related revenue.
Platform ValidationPositive partner Phase III results provide external validation for Inovio’s DNA medicine platform beyond its own pipeline. Successful clinical performance and favorable safety can strengthen partnering credibility, support future development programs, and improve the platform’s commercial potential.
Cost Control And RunwayLower operating expenses show progress in controlling the cost base, while new capital extends funding for clinical and prelaunch activities. Together, these actions provide additional time to pursue regulatory milestones and prepare commercialization without an immediate funding gap.
Bears Say
No Commercial RevenueThe company has not yet demonstrated a sustainable commercial revenue stream, leaving its operating model dependent on development progress, collaborations, and financing. Persistent losses indicate that any future earnings improvement remains contingent on regulatory approval and successful product commercialization.
Cash Burn And LiquidityHigh ongoing cash consumption and a limited projected runway constrain Inovio’s financial flexibility. Even after the equity raise, the company may need additional capital before operations become self-funding, creating financing dependence while it funds launch and pipeline activities.
Balance Sheet DeteriorationThe sharp reduction in equity has materially worsened leverage despite relatively modest absolute debt. A thinner capital base reduces resilience against operating setbacks, limits strategic flexibility, and can make future financing more important as the company continues to fund loss-making development programs.
Inovio Pharmaceuticals News
GBM FAQ
What was Inovio Pharmaceuticals’s price range in the past 12 months?
Inovio Pharmaceuticals lowest stock price was €0.56 and its highest was €2.28 in the past 12 months.
What is Inovio Pharmaceuticals’s market cap?
Inovio Pharmaceuticals’s market cap is €111.55M.
When is Inovio Pharmaceuticals’s upcoming earnings report date?
Inovio Pharmaceuticals’s upcoming earnings report date is Nov 10, 2026 which is in 57 days.
How were Inovio Pharmaceuticals’s earnings last quarter?
Inovio Pharmaceuticals released its earnings results on Aug 12, 2026. The company reported -€0.06 earnings per share for the quarter, beating the consensus estimate of -€0.186 by €0.126.
Is Inovio Pharmaceuticals overvalued?
According to Wall Street analysts Inovio Pharmaceuticals’s price is currently Undervalued.
Does Inovio Pharmaceuticals pay dividends?
Inovio Pharmaceuticals does not currently pay dividends.
What is Inovio Pharmaceuticals’s EPS estimate?
Inovio Pharmaceuticals’s EPS estimate is -0.17.
How many shares outstanding does Inovio Pharmaceuticals have?
Inovio Pharmaceuticals has 103,397,514 shares outstanding.
What happened to Inovio Pharmaceuticals’s price movement after its last earnings report?
Inovio Pharmaceuticals reported an EPS of -€0.06 in its last earnings report, beating expectations of -€0.186. Following the earnings report the stock price went down -1.949%.
Which hedge fund is a major shareholder of Inovio Pharmaceuticals?
Currently, no hedge funds are holding shares in DE:GBM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Inovio Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€2.72 (156.79% Upside)
€2.72 (156.79% Upside)
Blogger Sentiment
Bullish
DE:GBM Sentiment 100%
Sector Average ―
Sector Average ―
Technicals
SMA
Negative
20 days / 200 days
Momentum
-52.83%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-27.62%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Inovio Pharmaceuticals
Inovio Pharmaceuticals, Inc. is a biotechnology firm dedicated to the research, development, and market introduction of DNA-based treatments. Its core mission is to prevent and cure illnesses associated with human papillomavirus (HPV), various types of cancer, and infectious diseases. The company's advanced DNA medicine platform utilizes meticulously engineered SynCon sequences to precisely identify and optimize the genetic blueprint of a target antigen. This innovative approach is supported by its CELLECTRA smart device technology, which efficiently delivers the DNA plasmids. Inovio is actively engaged in and planning clinical trials for its DNA medicines across a wide array of conditions. These include HPV-related precancerous lesions, such as cervical, vulvar, and anal dysplasia; HPV-driven cancers affecting areas like the head and neck, cervix, anus, penis, vulva, and vagina; and other HPV-associated disorders like recurrent respiratory papillomatosis. Beyond HPV, its pipeline addresses glioblastoma multiforme, prostate cancer, and a range of infectious diseases, including HIV, Ebola, Middle East Respiratory Syndrome (MERS), and Lassa fever. The company benefits from a vast network of collaborators and partners, encompassing prominent academic institutions, government agencies, non-profit foundations, and pharmaceutical corporations. Key examples include AstraZeneca, The Bill & Melinda Gates Foundation, the Coalition for Epidemic Preparedness Innovations (CEPI), the Defense Advanced Research Projects Agency (DARPA), the National Institutes of Health, Regeneron Pharmaceuticals, and the University of Pennsylvania. Significant partnerships also involve an agreement with Richter-Helm BioLogics GmbH & Co. KG to further develop the investigational COVID-19 DNA vaccine INO-4800, alongside a strategic alliance with the International Vaccine Institute and Seoul National University Hospital. Established in 1979, Inovio Pharmaceuticals is headquartered in Plymouth Meeting, Pennsylvania.
GBM Company Deck
GBM Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed meaningful progress on the regulatory front (target PDUFA date, completed inspections, an FDA informal meeting) and tangible commercial/pipeline milestones (partner Phase III success, DPROT preclinical progress, Syneos engagement). Financially the company cut costs and completed an $18.3M equity offering that extends runway into late Q1 2027. However, material risks remain: near‑term liquidity is tight with an $18M projected Q3 burn, net loss improvement was substantially driven by a noncash warrant gain, regulatory uncertainties persist around accelerated approval eligibility and confirmatory trial design feedback, and competitive uptake of a rival product exists. Taken together, positives around regulatory momentum and platform validation are balanced by financing, regulatory, and execution risks.View all DE:GBM earnings summariesGBM Stock 12 Month Forecast
Average Price Target
€2.72
▲(156.79% Upside)